Literature DB >> 24938629

Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype.

Jose María López-Ayala1, Ivan Gómez-Milanés2, Juan José Sánchez Muñoz1, Francisco Ruiz-Espejo2, Martín Ortíz3, Josefa González-Carrillo1, David López-Cuenca1, M J Oliva-Sandoval1, Lorenzo Monserrat3, Mariano Valdés1, Juan R Gimeno4.   

Abstract

AIMS: Risk stratification for sudden death in arrhythmogenic right ventricular cardiomyopathy (ARVC) is challenging in clinical practice. We lack recommendations for the risk stratification of exclusive left-sided phenotypes. The aim of this study was to investigate genotype-phenotype correlations in patients carrying a novel DSP c.1339C>T, and to review the literature on the clinical expression and the outcomes in patients with DSP truncating mutations. METHODS AND
RESULTS: Genetic screening of the DSP gene was performed in 47 consecutive patients with a phenotype of either an ARVC (n = 24) or an idiopathic dilated cardiomyopathy (DCM), who presented with ventricular arrhythmias or a family history of sudden death (n = 23) (aged 40 ± 19 years, 62% males). Three unrelated probands with DCM were found to be carriers of a novel mutation (c.1339C>T). Cascade family screening led to the identification of 15 relatives who are carriers. Penetrance in c.1339C>T carriers was 83%. Sustained ventricular tachycardia was the first clinical manifestation in six patients and nine patients were diagnosed with left ventricular impairment (two had overt severe disease and seven had a mild dysfunction). Cardiac magnetic resonance revealed left ventricular involvement in nine cases and biventricular disease in three patients. Extensive fibrotic patterns in six and non-compaction phenotype in five patients were the hallmark in imaging.
CONCLUSION: DSP c.1339C>T is associated with an aggressive clinical phenotype of left-dominant arrhythmogenic cardiomyopathy and left ventricular non-compaction. Truncating mutations in desmoplakin are consistently associated with aggressive phenotypes and must be considered as a risk factor of sudden death. Since ventricular tachycardia occurs even in the absence of severe systolic dysfunction, an implantable cardioverter-defibrillator should be indicated promptly. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Arrhythmogenic cardiomyopathy; Desmoplakin; Dilated cardiomyopathy; Implantable cardioverter-defibrillator; Sudden death

Mesh:

Substances:

Year:  2014        PMID: 24938629     DOI: 10.1093/europace/euu128

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  31 in total

Review 1.  Precision medicine approach to genetic cardiomyopathy.

Authors:  K Filonenko; H A Katus; B Meder
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

2.  Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation.

Authors:  Ronald Ng; Heather Manring; Nikolaos Papoutsidakis; Taylor Albertelli; Nicole Tsai; Claudia J See; Xia Li; Jinkyu Park; Tyler L Stevens; Prameela J Bobbili; Muhammad Riaz; Yongming Ren; Christopher E Stoddard; Paul Ml Janssen; T Jared Bunch; Stephen P Hall; Ying-Chun Lo; Daniel L Jacoby; Yibing Qyang; Nathan Wright; Maegen A Ackermann; Stuart G Campbell
Journal:  JCI Insight       Date:  2019-06-13

Review 3.  Desmosome regulation and signaling in disease.

Authors:  Joshua A Broussard; Spiro Getsios; Kathleen J Green
Journal:  Cell Tissue Res       Date:  2015-02-19       Impact factor: 5.249

4.  Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

Authors:  Deniz Akdis; Corinna Brunckhorst; Firat Duru; Ardan M Saguner
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

5.  Nature and Nurture in Arrhythmogenic Right Ventricular Cardiomyopathy - A Clinical Perspective.

Authors:  Cynthia A James
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01

6.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Eric D Smith; Neal K Lakdawala; Nikolaos Papoutsidakis; Gregory Aubert; Andrea Mazzanti; Anthony C McCanta; Prachi P Agarwal; Patricia Arscott; Lisa M Dellefave-Castillo; Esther E Vorovich; Kavitha Nutakki; Lisa D Wilsbacher; Silvia G Priori; Daniel L Jacoby; Elizabeth M McNally; Adam S Helms
Journal:  Circulation       Date:  2020-05-06       Impact factor: 29.690

Review 7.  Genetics of and pathogenic mechanisms in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Anita Kiran Vimalanathan; Elisabeth Ehler; Katja Gehmlich
Journal:  Biophys Rev       Date:  2018-07-11

8.  Creating a 'Molecular Band-Aid'; Blocking an Exposed Protease Target Site in Desmoplakin.

Authors:  Catherine A Hoover; Kendahl L Ott; Heather R Manring; Trevor Dew; Maegen A Borzok; Nathan T Wright
Journal:  J Pers Med       Date:  2021-05-12

Review 9.  Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Authors:  Nicoletta Orphanou; Efstathios Papatheodorou; Aris Anastasakis
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

10.  The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.

Authors:  Leila Rouhi; Siyang Fan; Sirisha M Cheedipudi; Aitana Braza-Boïls; Maria Sabater Molina; Yan Yao; Matthew J Robertson; Cristian Coarfa; Juan R Gimeno; Pilar Molina; Priyatansh Gurha; Esther Zorio; Ali J Marian
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.